Resolution of psoriatic lesions on the gingiva and hard palate following administration of adalimumab for cutaneous psoriasis.
We report the case of a 51-year-old man who presented with an atypical inflammatory response of the gingiva and hard palate that was concomitant with widespread cutaneous psoriasis. The patient had discontinued taking adalimumab 6 months prior to presentation, having achieved satisfactory management of his cutaneous lesions; however, he resumed 2 days prior to presentation due to recurrent disease. A gingival biopsy was consistent with oral psoriasis. At a 2-month follow-up, dramatic resolution of oral involvement was evident and the cutaneous psoriatic plaques were greatly reduced in size. The administration of adalimumab for cutaneous psoriasis may concurrently modulate oral dissemination.
Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, Baltimore, USA.
John K
JK
Brooks
Department of Periodontics, University of Maryland School of Dentistry, Baltimore, USA.
Justin W
JW
Kleinman
Department of Dermatology, University of Maryland School of Medicine, Baltimore, USA.
Charlotte E
CE
Modly
Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, Baltimore, USA.
John R
JR
Basile
D000068879:Adalimumab / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D005882:Gingival Diseases / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D021362:Palate, Hard / Q000473:pathology*; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000068879:Adalimumab